PMID- 38310479
OWN - NLM
STAT- Publisher
LR  - 20240204
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
DP  - 2024 Jan 16
TI  - Comparative Effectiveness of Oral Hypoglycemic Agents for Glycemic Control and 
      Glycemic Variability in Patients with Type 2 Diabetes Mellitus: Using Flash 
      Glucose Monitoring.
LID - 10.2174/0115733998267817231227102553 [doi]
AB  - AIM: The study aimed to compare the effectiveness of oral hypoglycemic agents 
      (OHAs) as monotherapy, dual and quadruple therapy for glycemic control (GC) and 
      glycemic variability (GV) in patients with type-2 diabetes (T2DM) using flash 
      glucose monitoring system (FGM). BACKGROUND: Diabetes management largely relies 
      on HbA1c monitoring. Glycemic variability (GV) has been an evolving glycemic 
      target for preventing complications related to type 2 diabetes mellitus (T2DM). 
      OBJECTIVE: The purpose of the study was to compare glycemic control (GC) measures 
      and glycemic variability (GV) measures among study groups and to study the 
      relationships between GC and GV indices. METHODS: Retrospectively, FGM data were 
      collected from 50 T2DM patients. The patients were classified based on prescribed 
      number of OHAs as monotherapy [group 1: dipeptidyl peptidase- 4 (DPP-4) 
      inhibitors (n=10), group 2: sodium-glucose co-transporter-2 (SGLT2) inhibitors 
      (n=10), group 3: sulphonylureas (n=10), group 4: dual therapy (n=10), and group 
      5: quadruple therapy (n=10)]. Measures of GC and GV were evaluated. RESULTS: 
      Significant differences between study groups were observed in GC and GV 
      measurements. The SGLT2 inhibitors monotherapy group demonstrated optimal GC 
      [eA1c (%): 6.5 +/- 2.2; MBG: 140.80 +/- 63.94; TIR: 60.60 +/- 19.96] and GV (SD: 42.38 
      +/- 34.57; CV: 27.85 +/- 6.68; MAGE: 96.76 +/- 52.47; MODD: 33.96 +/- 22.91) in 
      comparison to other study groups. On using Pearson correlation analysis, mean 
      blood glucose (MBG) and mean amplitude of glycemic excursion (MAGE) showed 
      moderate correlation (r = 0.742)(r2 = 0.551), depicting distinct glucose 
      variabilities at the same mean blood glucose levels. CONCLUSION: The monotherapy 
      group of SGLT2 inhibitors demonstrated glucose-lowering effects with reduced 
      glycemic variability. Hence, optimum glycemic control is associated with 
      decreased glycemic variability.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Venkatachalapathy, Poongothai
AU  - Venkatachalapathy P
AUID- ORCID: 0000-0002-1203-3841
AD  - Department of Pharmacy Practice, Karpagam College of Pharmacy, Coimbatore, Tamil 
      Nadu, India.
FAU - Mohandoss, Karthik Kumar Dos Alagarswamy
AU  - Mohandoss KKDA
AD  - Department of Obesity and Diabetes, GEM Hospital and Research Centre, Coimbatore, 
      India.
FAU - Munisamy, Murali
AU  - Munisamy M
AUID- ORCID: 0000-0002-7775-3428
AD  - Translational Medicine Centre, All India Institute of Medical Sciences, Bhopal, 
      Madhya Pradesh, India.
FAU - Sellappan, Mohan
AU  - Sellappan M
AUID- ORCID: 0000-0002-4026-9405
AD  - Department of Pharmacy Practice, Karpagam College of Pharmacy, Coimbatore, Tamil 
      Nadu, India.
LA  - eng
PT  - Journal Article
DEP - 20240116
PL  - United Arab Emirates
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
SB  - IM
OTO - NOTNLM
OT  - Glycemic control
OT  - ambulatory glucose profile.
OT  - flash glucose monitoring
OT  - glycemic variability
OT  - oral hypoglycemic agents
OT  - type 2 diabetes mellitus
EDAT- 2024/02/04 12:42
MHDA- 2024/02/04 12:42
CRDT- 2024/02/04 08:33
PHST- 2023/08/15 00:00 [received]
PHST- 2023/10/30 00:00 [revised]
PHST- 2023/11/16 00:00 [accepted]
PHST- 2024/02/04 12:42 [medline]
PHST- 2024/02/04 12:42 [pubmed]
PHST- 2024/02/04 08:33 [entrez]
AID - CDR-EPUB-137420 [pii]
AID - 10.2174/0115733998267817231227102553 [doi]
PST - aheadofprint
SO  - Curr Diabetes Rev. 2024 Jan 16. doi: 10.2174/0115733998267817231227102553.